[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Authors: Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Craig Gedye, Natalie Rutherford, Shahneen Sandhu, Aravind Ravi Kumar, David Pook, Shakher Ramdave, David Nadebaum, Mark Voskoboynik, Andrew Redfern, W A Macdonald, Laurence E. Krieger, Geoffrey Schembri, Wei Chua, Peter Lin, Lisa G. Horvath, Patricia Bastick, Patrick Butler, Alison Yan Zhang, Sonia Yip, Hayley Thomas, Ailsa Langford, Michael S. Hofman, Margaret McJannett, Andrew Martin, Martin R. Stockler, Ian D. Davis - The Lancet 2024 cited by 155